Metastatic Cervical Cancer Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about Metastatic Cervical Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2Phase 3

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Recurrent Cervical CancerMetastatic Cervical CancerPersistent Cervical Cancer
N.N. Alexandrov National Cancer Centre120 enrolled1 locationNCT07472153
Recruiting
Phase 2

A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.60 enrolled2 locationsNCT07051486
Recruiting
Phase 2

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Cervical CancerRecurrent Cervical CarcinomaHPV-Related Malignancy+2 more
Precigen, Inc46 enrolled3 locationsNCT06157151
Recruiting
Phase 2

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Cervical CancerMetastatic Cervical Cancer
Georgetown University35 enrolled4 locationsNCT04865887
Recruiting

Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy

Cervical CancerLocally Advanced Cervical CancerRecurrent Cervical Cancer+1 more
MSD Italia S.r.l.200 enrolled11 locationsNCT06771193
Recruiting
Phase 1Phase 2

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.100 enrolled1 locationNCT06859775
Recruiting
Phase 2

Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.

Persistent, Recurrent, or Metastatic Cervical Cancer
Instituto Nacional de Cancer, Brazil44 enrolled1 locationNCT06670911